CN112233765A - Intelligent analysis method, system and equipment for repeated medication - Google Patents

Intelligent analysis method, system and equipment for repeated medication Download PDF

Info

Publication number
CN112233765A
CN112233765A CN202011114977.8A CN202011114977A CN112233765A CN 112233765 A CN112233765 A CN 112233765A CN 202011114977 A CN202011114977 A CN 202011114977A CN 112233765 A CN112233765 A CN 112233765A
Authority
CN
China
Prior art keywords
medication
repeated
scheme
analysis
information
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011114977.8A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202011114977.8A priority Critical patent/CN112233765A/en
Publication of CN112233765A publication Critical patent/CN112233765A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

The invention discloses a method, a system and equipment for intelligently analyzing repeated medication, wherein a repeated medication database is established, the medication use information is compared with the related information and rules of the repeated medication database, the repeated medication condition of a patient is analyzed, if repeated medication possibly exists among the medications, the related rationality and compliance of the repeated medication of the patient are evaluated according to the influence of the repeated medication on/in a group of the medications possibly existing and the comprehensive comparative analysis condition of an original medication scheme and a medication optimization scheme, and related application information is generated. By the method, the system and the equipment for intelligently analyzing repeated medication, a prescriber is assisted to provide a more reasonable and compliant medication scheme for a patient, bad repeated medication is reduced, and the safety, the effectiveness and the economy of medication of the patient are improved.

Description

Intelligent analysis method, system and equipment for repeated medication
Technical Field
The invention relates to the technical field of intelligent medical information processing, in particular to a method, a system and equipment for intelligently analyzing repeated medication.
Background
Whether the medicine is taken by the patient is reasonable or not is directly related to effective treatment of diseases, reasonable distribution of medical resources, medicine taking safety of the patient and the like, and is the key for controlling medical quality, controlling unreasonable medical expenses and guaranteeing the rights and interests of the patient.
China is a large country for producing medicine varieties, and medicines are various in types, complex in name and disordered in use and management of medicine names. Especially, the Chinese medicine, the Chinese patent medicine and the compound preparation produced by the Chinese medicine and the western medicine which are unique in China have the phenomena of multiple varieties, multiple names of one medicine, same-tone character medicine names, same-name different medicines and the like. In the actual prescription process, similar medicines or medicines with the same components are used together easily due to incomplete medicine information control, difficult acquisition of individualized information of patients, human errors and the like, so that the dosage is added, the adverse reaction is increased, the effect and the toxic and side effects are enhanced, and the like. If the composition is used properly, a better curative effect can be obtained, otherwise, the composition usually causes economic loss to patients, and is life-threatening to patients. Therefore, it is necessary to manage the medication phenomenon of the same kind of drugs or drugs having the same ingredients in common to ensure the rationality of the use of the drugs.
The existing method and system for analyzing repeated medication exhaust the combination of the same kind of medicines or medicines with the same components and establish a knowledge base, and facilitate the inquiry of a user and prompt related repeated medication risks in the process of prescription or retrospective analysis afterwards through an information system. In the actual process of the drug treatment of the patient, whether repeated drug administration exists among the drugs or not is considered, influence of the repeated drug administration and feasibility and benefit of optimization of the drug administration scheme of the patient are comprehensively considered, whether the drug administration scheme of the patient is reasonable or not can be comprehensively evaluated and judged, and whether the drug administration scheme needs to be adjusted or not is comprehensively balanced and analyzed.
Repeated medication and related analysis relate to a large amount of information, data and rules, therefore, an information technology is applied, medical and pharmaceutical professional data and services are combined, a set of practical and comprehensive repeated medication analysis rules are established, a related analysis system is established, an optimization scheme for repeated medication in the medication of patients and the influence of benefit and repeated medication are comprehensively analyzed, doctors and pharmacists can be helped to timely find and accurately analyze repeated medication problems in the medication scheme of patients, and the safety, effectiveness, economy and compliance of the medication of patients are greatly improved.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: aiming at the possible influence and damage of repeated medication on the treatment of a patient caused by the fact that the patient uses two or more similar medicines or medicines with the same components together, the method, the system and the equipment for intelligently analyzing the repeated medication are provided, and a prescriber and a pharmacist are helped to find out potential medication risks of the patient and reasonably take the medication of the patient.
The invention provides a method for intelligently analyzing repeated medication, which comprises the following steps:
a repeated medicine-taking database is established,
the information of the use of the medicine is extracted,
the medicine use information is compared with the related information and the rules of the repeated medicine database, the repeated medicine use condition is analyzed,
if there may be repeat dosing between drugs, a dosing optimization plan is generated,
the repeat-use database includes information and rules common to the same type of medication or medications having the same composition under different conditions of use.
The method for intelligent analysis of repeat medication as described above, the method further comprising: and carrying out comprehensive analysis and comparison according to the original medication scheme and the medication optimization scheme, and evaluating the reasonability of repeated medication of the patient.
The method for intelligent analysis of repeat medication as described above, the method further comprising: the extraction range of the medicine use information can be adjusted according to the current medicine use condition of the patient.
The method for intelligent analysis of repeat medication as described above, the method further comprising: if the information needed by certain analysis items is lacked due to incomplete related medicine use information in the process of repeated medicine use analysis, one of measures of ignoring, reminding and supplementing, supplementing according to settings, forcibly supplementing and the like is taken according to the specific situation of the lacked information.
The method for intelligent analysis of repeat medication as described above, the method further comprising: analyzing the possible influence of repeatedly-used medicines on a patient when the medicines are used according to different medicine use schemes under different medicine use conditions, and setting the corresponding grade/score of the related influence in each repeated-use influence analysis item; establishing a repeated medication influence comprehensive analysis model for synthesizing analysis results of repeated medication influence analysis items according to business requirements; the comprehensive grade/score of the influence of the drug pair/group combination on the repeated drug administration of the patient can be analyzed through the corresponding grade/score in each repeated drug administration influence analysis project and the comprehensive analysis model of the repeated drug administration influence under different use conditions according to different drug use schemes.
The method for intelligent analysis of repeated medication use as described above, wherein the medication optimization scheme comprises: adjusting at least one of a combination scheme of related drugs, adjusting related drugs, performing related medication monitoring or other treatment methods, and the like.
The method for intelligent analysis of repeat medication as described above, the method further comprising: under different use conditions, carrying out comprehensive rationality analysis and comparison on the medication optimization scheme and the original medication scheme, and setting the corresponding grade/score of different analysis results of relevant rationality analysis items of the medication scheme in each analysis item; setting a medication scheme comprehensive analysis model combining each rationality analysis project of the medication scheme according to business requirements; analyzing the medication optimization scheme and the original medication scheme through a comprehensive analysis model to obtain respective reasonability comprehensive grade/score; and comparing the rationality comprehensive analysis results of the medication optimization scheme and the original medication scheme, and evaluating the rationality of the original medication scheme.
The method for intelligent analysis of repeat medication as described above, the method further comprising: according to the business requirements and settings of different users, the results of the repeated medication analysis of the patient medication scheme can be as follows: at least one of reasonable, reminding, warning, prohibiting, prompting, recommending, guiding and the like.
A method of intelligent analysis of repeat medication, the method further comprising: the repeated medication database can also comprise the optimal medication scheme or the optimized medication scheme related to the repeated medication under different using conditions, and is applied to at least one item of auditing, recommending, analyzing, evaluating and managing the medication scheme of the patient.
The method for intelligent analysis of repeat-of-medication as described above, further comprising recommending a repeat-of-medication remediation regimen for a treatment goal not being met by a repeat-of-medication between medications. The repeated medication database can also comprise repeated medication remedy rules, and the medication use information and the medication treatment results are compared with the related information and rules in the repeated medication database to recommend a corresponding repeated medication remedy scheme.
The invention also provides a system for intelligently analyzing repeated medication, which comprises:
a database unit for storing a repeat medication database,
an information extraction unit for extracting drug use information,
a repeated medication analysis unit for comparing the medication use information with the related information and rules of the repeated medication database, analyzing the repeated medication situation of the patient, generating a medication optimization scheme if repeated medication possibly exists among the medications, and generating a repeated medication management scheme according to the situation of comprehensive comparison and analysis of the original medication scheme and the medication optimization scheme,
and the output unit is used for outputting the analysis result related to repeated medication and the management scheme.
The invention also provides a device for intelligently analyzing repeated medication, which comprises:
a database module for storing a repeat medication database,
an information extraction module for extracting the drug use information,
the repeated medication analysis module is used for comparing the medication use information with the related information and rules of the repeated medication database, analyzing the repeated medication condition of the patient, generating a medication optimization scheme if repeated medication possibly exists among the medications, generating a repeated medication management scheme according to the comprehensive comparison and analysis condition of the original medication scheme and the medication optimization scheme,
and the output module is used for outputting the related analysis result of the repeated medication and the management scheme.
According to the method, the system and the equipment for intelligently analyzing the repeated medication, the repeated medication database is established, the medication use information is compared with the related information and the rules of the repeated medication database, the repeated medication condition of a patient is analyzed, if repeated medication possibly exists among the medications, the related rationality and the compliance of the repeated medication of the patient are evaluated according to the influence of the repeated medication on the repeated medication/the group possibly existing in the repeated medication, and the comprehensive comparison and analysis condition of the original medication scheme and the medication optimization scheme is carried out, and the related application information is generated. By the method, the system and the equipment for intelligently analyzing repeated medication, a prescriber is assisted to provide a more reasonable and compliant medication scheme for a patient, bad repeated medication is reduced, and the safety, the effectiveness and the economy of medication of the patient are improved.
Drawings
FIG. 1 is a flow chart of a method of repeat-of-medication management in accordance with the present invention.
FIG. 2 is a block diagram of a system for repeat-of-medication management in accordance with the present invention.
Fig. 3 is a hardware block diagram of an apparatus for repeat medication administration of the present invention.
Detailed Description
To further explain the technical means and effects of the present invention adopted to achieve the intended purpose, the following detailed description of the embodiments of the present invention is provided in conjunction with the accompanying drawings and examples.
In the present invention, the patient refers to the subject to which the medicine is actually used. The prescriber refers to a person who makes or manages a prescription of a medicine, such as a doctor or a pharmacist. The user refers to a user who applies the analysis method of the present invention. The prescription refers to the proof for using medicine prescribed for the patient, and includes prescription, medical order, etc. The medicine is used for preventing, treating and diagnosing human diseases, purposefully regulating the physiological function of human and prescribing substances with indications or functional indications, administration methods and dosage, and comprises traditional Chinese medicinal materials, traditional Chinese medicine decoction pieces, Chinese patent medicines, botanical medicines, animal medicines, gene medicines, chemical bulk drugs and preparations thereof, biological products, radiopharmaceuticals, serum, vaccines, blood products, diagnostic medicines and the like.
In the present invention, the drug use conditions include: at least one of basic information of the patient, genetic information, disease information, medical history information, medication history information, operation information, physiological status, psychological/intellectual status, life information, environmental information, medical insurance information, medical condition, and the like. Wherein the patient basic information comprises: age, gender, race/ethnicity, marital status, etc.; the genetic information includes: genetic information, genetic information mutation/change information, genetic defect information, genetic medical history, family medical history and the like; the disease information includes: disease information, index, symptom type, symptom, pulse condition, tongue diagnosis, allergy information, etc.; the medical history information includes: history of disease, history of surgery, history of radiotherapy, history of chemotherapy, history of psychotherapy, history of physical therapy, history of immunotherapy, history of gene therapy, etc.; the medication history information includes: the medication history, the curative effect of the medicine, the adverse reaction of the medicine, the allergic history of the medicine, the tolerance condition of the medicine and the like; the operation information includes: surgery, examination, test, detection, operation, health care, rehabilitation, psychotherapy, radiotherapy, chemotherapy, physiotherapy, thermotherapy, phototherapy, magnetotherapy, electrotherapy, cryotherapy, electromagnetic therapy, phonotherapy, immunotherapy, gene therapy, etc.; the physiological states include: developmental status, fertility status, physiological functions, etc., wherein the physiological functions include: physical, nutritional, hearing, vision, taste, smell, touch, respiration, motor coordination, digestion, absorption, excretion, sexual function, and related ability levels; psychological/intellectual states include: mental, emotional, sensory, intellectual, attention, memory, perception, communication, expression, etc.; the life information includes: diet, work, study, exercise, entertainment, etc.; the environment information includes: geographic location, season, climate, air pressure, humidity, altitude, lighting, air quality, plants, microbes, noise, radiation, epidemics, sanitary conditions, etc.; the medical insurance information includes: medical welfare, medical insurance, commercial insurance payment conditions, etc.; the medical conditions include: medical institution level, specialty, attribute, region, department, medical personnel, protective measures, etc.
In the present invention, the drug administration protocol comprises: the information such as the drugs used by the patients and the use time, use method, use amount and the like of each drug specifically comprises at least one item of administration route, administration part, use method, administration amount, administration time, administration interval, administration frequency, administration period and the like, and the drug information comprises: the common name, trade name, manufacturing enterprise, batch number, type, specification, dosage form, etc. of the drug.
A first embodiment of the present invention is described with reference to fig. 1. FIG. 1 is a flow chart of a method of repeat-of-medication management in accordance with the present invention. As shown in the figure, the method for managing repeated medication of the invention comprises the following steps:
step 1: and establishing a repeated medication database.
The repeat-use database includes repeat-use that may occur for a drug pair/group combination under different use conditions, as well as related information and rules. The related rules of repeated administration of drug pairs/groups refer to the related information and rules of the effect generated when the same type of drugs or drugs with the same components are used together according to a certain drug administration scheme under certain conditions of use, including the case that two or more than two same type of drugs or drugs with the same components are used together, and the use together refers to the simultaneous use or the use within a period of time. Under certain use conditions, two or more than two similar medicines or medicines with the same component which can be repeatedly used are taken together, namely a repeatedly used medicine pair/group.
The method for intelligently analyzing repeated medication as described above includes, but is not limited to, using two or more drugs with the same composition together, using two or more similar drugs together, using two or more drugs with the same composition or similar drugs together under certain usage conditions, using two or more drugs with the same composition or similar drugs together, and using the same composition or similar drugs with the same composition or the composition or similar drugs exceeding a certain usage amount. The certain amount includes, but is not limited to, the maximum amount, the amount conventionally used, and the like.
According to the method for intelligently analyzing repeated medication, the judgment conditions of the repeated medication medicine pairs/groups can be different, the judgment conditions of different repeated medication medicine pairs/groups can be different, and the judgment conditions of the same repeated medication medicine pairs/groups can also be different under different use conditions. Analyzing the possible influence of two or more similar medicines or medicines with the same components on a patient under different use conditions based on mass data, and setting the corresponding grade/score of the related influence under different use conditions in each repeated medicine use influence analysis project; the repeated medication comprehensive influence analysis model for synthesizing each repeated medication influence analysis item under different use conditions can be set according to business requirements; the comprehensive influence level/score of the repeated medication on the patient under different use conditions can be analyzed through the corresponding level/score of the influence of the medication on the combination in each repeated medication influence analysis project and the comprehensive influence analysis model of the repeated medication. Setting a certain comprehensive influence level/score as a critical value, and when the comprehensive influence level/score is higher than the critical value, determining that the medicine pair/combination possibly has repeated use, otherwise, determining that the repeated use possibly does not exist. And analyzing the use conditions and the drug use scheme of the drug pairs/groups with possible repeated drug use so as to obtain judgment conditions of different repeated drug use drug pairs/groups.
The method for intelligent analysis of repeat medication as described above, the method further comprising: the user can select or adjust the judgment condition of the repeated medication drug pair/group according to the self business requirement on the basis of the unified repeated medication database so as to support the relevant requirements of self reasonable and compliance medication management on the rules. The selection or adjustment method can be the selection or adjustment of the critical value of the comprehensive influence level/score of the heavy multiplexing drugs, can also be the direct selection or adjustment of the judgment conditions of the pair/group of the heavy multiplexing drugs, and can also be both. The range of selection or adjustment may be for all medications, may be for individual medications, may be for certain types of medications, and may be for certain types of business scenarios (e.g., people, diagnoses, departments, etc.).
The repeat-of-medication related rules in the repeat-of-medication database may also include information and rules related to repeat-of-medication and related-medication monitoring regimens, with the specific monitoring comprising: monitoring the blood concentration of related medicaments, monitoring related indexes, monitoring related symptoms, monitoring related physiological conditions and the like, and is used for acquiring and analyzing the actual conditions related to repeated medicament administration in the medicament using process or after the medicament is used.
The repeat-use database may also include information and rules related to analysis of the rationality of a drug use regimen.
The related information and rules of the repeat-use database include various related elements and values/ranges/calculation methods/sources/restrictions/exclusion conditions of the respective elements, interrelations/interactions/interconversions/rules/calculation methods between the respective/groups/types of elements, and the like.
The repeat-of-use related information and rules of the present invention include: the drug composition rules, the drug applicability/application range rules, the antibacterial spectrum related rules of antibacterial drugs, the usage amount rules of drugs, the usage time rules of drugs, the treatment course rules of drugs, the usage method rules of drugs, the pharmacological classification rules of drugs, the mechanism-of-action related rules of drugs, the pharmacokinetics related rules of drugs, the withdrawal related rules of drugs, the adverse drug reaction rules, the combination related rules, the price related rules of drugs, the medical insurance/medical welfare rules of drug use, and the like.
The repeat-of-use related information and rules of the present invention further comprise: information and rules regarding drug use conditions, drug use regimens, and drug pair/group repeat type/repeat level/repeat effect, which in turn can be divided into repeat effect type and effect level, and specific effect outcome.
Wherein the types of repeat administrations may include: the medicine containing the same components is used together, such as a valsartan capsule and a valsartan amlodipine tablet are used together; the same kind of medicines are used together, such as a valsartan capsule and an irbesartan tablet which are used together. The above components include effective components, adjuvant components, parent drug, prodrug, metabolite, etc. The similar drugs comprise drugs with the same or similar pharmacological classification or action mechanism, drugs with the same or similar clinical action, drugs with overlapped or partially overlapped antibacterial spectrum, and the like. The type of repeat-use effect may include: enhancement/reduction of efficacy, shortening/extension of onset time, enhancement/reduction of adverse effects, increase/reduction of toxicity, increase/reduction of treatment cost, enhancement/reduction of compliance, etc.; repeat use impact levels can be set to negligible, mild, moderate, severe, dangerous, forbidden, etc.
Wherein the drug use scheme refers to a use scheme of two or more drugs which can be repeatedly used under certain use conditions, and comprises the following steps: the application time scheme, the application amount scheme and the application method scheme of two or more similar medicines or medicines containing the same components are used together, and specifically comprise the following steps: the sequence of the use of the medicines, the medication time interval between the medicines, the medication time, the administration part of each medicine, the administration route, the dosage, the administration frequency, the administration course and the like.
Relevant information and rules of reasonableness analysis of drug use schemes in the repeated drug use database include, but are not limited to, dimension interrelations and rules of effectiveness, safety, economy, suitability and the like of different drug use schemes and drugs under different drug use conditions. The validity-related analysis and rules may include: applicable population, medication purpose, indication/applicable condition, effective rate, onset time and the like, and can also comprise the importance degree of the medication purpose corresponding to the medicine, the importance degree of the medicine in a treatment scheme and the like; the security correlation analysis and rules may include: at least one item of contraindication, cautionary events, adverse reactions, interaction, allergy and the like; the economic relevance analysis and rules may include: at least one item of price, treatment cost, medical insurance situation, administrative management requirement and the like; the suitability correlation analysis and rules may include: availability, difficulty of use, taste/smell, frequency of use, time of use, etc.
The repeat medication database of the present invention is based on various product specifications, guidelines, clinical treatment routes, prescription sets, pharmacopoeias, expert consensus, conference disciplines and consensus within the conjunctions of medicine/hospital/department, industry norms, textbooks, treatises, writings, inventions, scientific inferences, experimental reports, data analysis reports, test reports, examination reports, approval documents, relevant regulations, relevant guidelines, relevant policies, relevant regimes, relevant catalogs, relevant documentation, relevant price specifications, relevant price catalogs, relevant bidding results, relevant price policies, relevant insurance payment agreements, relevant insurance payment terms, relevant bidding results, relevant purchasing catalogs, relevant doctors/nurses/pharmacists/nursing staff/users/salespersons, use evaluation/use results/use monitoring reports/safety reports, Other literature data, other research results with professionalism/authority, a method based on evidence medicine, probability speculation based on existing data, a medical/pharmaceutical data model established by sources such as various weights, various grades, various orders and the like needing to be set manually, a database established based on information reforming, information analysis and big data analysis, a database established through artificial intelligence deep learning, a database obtained through data mining and analysis, and at least one of rules set manually through data statistical analysis and artificial intelligence deep learning.
Step 2: drug use information is extracted.
The drug use information includes: drug use conditions and drug use regimens. The information such as the drug use information such as basic information, genetic information and disease information of the patient, the drug used by the patient, the use time, use method and use amount of each drug, and the like are extracted, specifically, the information includes drug use scheme information such as administration route, administration part, use method, administration amount, administration time, administration interval, administration frequency and administration period, and is used for analyzing the repeated administration condition of the drug used by the patient.
The medicine use information of the patient can be extracted in the range of prescriptions and medical orders, can also be extracted by combining the prescriptions and medical orders of the patient, and can also comprise the medicine information used by the patient.
The way of extracting the medicine use information can be to obtain the medical orders, medical records, prescriptions, electronic medical records, examination/inspection/detection reports and the like of the patients through a related information system, and can also be to improve the related information through inquiry/communication. The information sources may also include personal information repositories, health profiles, family or family member health records, medical facility information systems, pharmacy/medical device store information systems, medical records, treatment records, assessment reports, consultation records, survey records, work records/plans, dietary records/plans, medication records/plans, treatment records/plans, exercise records/plans, work records/plans, learning records/plans, rehabilitation records/plans, healthcare records/plans, test/exam orders, surgical plans/records, health management plans, billing orders, clinical treatment routes, exam/test results, medical device usage settings/records, gene testing results, and may also be obtained from usage information/usage records of the medical device itself, or obtained from the use/prescription/recommendation/sale records of patients/doctors/nurses/pharmacists/caregivers/salespeople, or provided by various wearing devices, sensors, electronic devices, electronic positioning systems, weather forecast systems, electronic temperature/humidity/air pressure detection devices, intelligent sound boxes, intelligent home systems, intelligent monitoring/monitoring systems, intelligent glasses, intelligent toilets, intelligent floors, intelligent scales, intelligent detection/analysis devices, electronic infusion systems, surgical robots, face recognition analysis, fingerprint recognition, voice recognition, gait recognition, positioning systems, social platforms and other devices or systems, or obtained by the big data analysis of the information of patients' lives, studies, works, sports, trips, social interactions, shopping, diet, work, entertainment and the like, the information can also be analyzed by the patient's race/family/region/age/marital/birth, etc. The missing information can also be provided or refined by the patient/doctor/nurse/pharmacist/caregiver, or the highly relevant information can be actively prompted to the patient/doctor/nurse/pharmacist/caregiver/salesperson to observe, monitor, check, inquire, analyze, confirm, record whether the relevant condition occurs or obtain the relevant index/performance/feeling/symptom/physiological change.
In the invention, the extraction of the medicine use information can also adjust the extraction range of the related information according to the current medicine use information of the patient. The time frame over which repeated dosing of different drugs may occur differs from that of other drugs. When the medicine use information is extracted, the time range of the extraction can be determined according to the time that the repeated medication of each medicine and other medicines possibly exists in the medicines used by the patient; or extracting the relevant information by taking the time when the medicine of which the patient focuses attention in the medicines and other medicines possibly have repeated medicines as the extracted time range; or the related information can be prompted to the prescriber, and the prescriber sets the information extraction time range; the information extraction time range correlation rule can also be set according to the importance of the medicine in repeated medicine analysis under different use conditions and the time range of the medicine in which repeated medicine possibly occurs, and the information can be extracted according to the time range in the correlation rule. All patient medication information in the information extraction range is combined to perform repeated medication analysis, so that possible repeated medication omission caused by insufficient information acquisition range can be avoided, and hidden dangers are brought to the medication of the patient.
In the invention, if incomplete use condition information/patient information of related medicines is generated in the process of repeated medicine analysis, so that medicine use information/patient information required by certain analysis items is lacked, one of measures of ignoring, reminding supplementation, supplementing according to settings, forcing supplementation and the like is taken according to the specific situation of the lacked information. The specific measures can be selected manually, or corresponding rules of the information items and the processing measures which are lacked under different using conditions can be set, and the system recommends or takes corresponding measures according to the set rules.
In the present invention, a patient personal information database may also be included for storing patient related information and providing or supplementing patient related information for repeat medication analysis. The patient personal information database comprises the relevant information of the patient, and the content comprises: patient basic information, genetic related information, family health related information such as family medical history, allergy history, regional epidemic history, medication history, surgical history, learning status, work status, exercise status, family status, living environment, hobbies, compliance status, tolerance status, medical insurance status, and information such as physiology/psychology/learning/work/physical/sleep/exercise/mood/metabolism/vision/intelligence/attention/diet/immunity/growth development/memory/fertility status and work and rest time.
In the invention, a personal business database of the prescriber can be further included, which is used for extracting the medicine use information of the patient and providing relevant prescriber habits of the prescriber for repeated medicine use analysis so as to accurately analyze the true situation of the medicine use.
And step 3: the drug administration analysis was repeated.
And comparing the drug use information with the related information and rules of the repeated drug use database, and analyzing the repeated drug use condition of the patient.
According to the acquired medicine use information of the patient, such as the medicine use condition, the medicine use scheme and the like, the obtained information is compared with the related information and the rules of repeated medicine use, and whether the situation that repeated medicine use possibly exists in the medicine used by the patient under the use condition or not and the situation that the type of repeated medicine use/the influence level of repeated medicine use/the consequence of repeated medicine use possibly exist are analyzed.
The invention also includes: analyzing the possible influence of the repeated-use medicine pair/combined use on the patient under different use conditions, and setting the corresponding grade/score of the relevant influence under different use conditions in each repeated-use influence analysis item; the repeated medication comprehensive influence analysis model for synthesizing each repeated medication influence analysis item under different use conditions can be set according to business requirements; the comprehensive influence level/score of the repeated medication on the patient under different use conditions can be analyzed through the corresponding level/score of the influence of the medication on the combination in each repeated medication influence analysis project and the comprehensive influence analysis model of the repeated medication.
The effect of repeated administration can be analyzed from the safety, efficacy, economy, fitness, etc. of the patient's administration, e.g., analysis of the effect of repeated administration in terms of safety can include: changes in the severity of the original adverse effects, etc.; the effectiveness aspect analysis items may include: the economic analysis items may include the impact on the efficacy and severity of the treatment, etc.: increased treatment costs and money amounts, etc.; the suitability aspect analysis items may include: influence of compliance with medication, etc. When the comprehensive influence of repeated medicine application on a patient is analyzed, a comprehensive influence analysis model formed by analysis results of analysis items can be set according to the business requirements of different business units, so that quantitative evaluation results of the comprehensive influence can be obtained according to the relation between the analysis items and the comprehensive influence results and the analysis results of the repeated medicine application on the analysis items. The business unit may be an analysis unit that divides a business scenario in each dimension and combination of administration, medical institution, department, doctor, patient, medicine, disease, and the like. The repeated medication comprehensive influence analysis model can be set by a user or can be a model established after analysis of big data and artificial intelligence.
F is the comprehensive influence grade/score of repeated drug administration of drug pairs/combination on patients under certain use conditions, FiCorresponding grade/score in the ith repeat dosing impact analysis project for relevant impact, S (f)i) Is the formula of the result of the ith repeated medication influence analysis item in the comprehensive influence analysis model. The specific calculation formula is as follows,
Figure BDA0002729705370000171
such as: the influence of the analysis items such as safety, effectiveness, economy, suitability, etc. can be set to 1 to 5 levels, and the higher the level, the more adverse the influence. It is hypothesized that type 2 diabetic patients use metformin in combination with glyburide. In the aspect of safety, severe hypoglycemia occurs due to the combination of the two medicines, and the level of the influence in a safety analysis project is assumed to be 4; in terms of effectiveness, glycemic control is up to standard, assuming that the impact is on a level of 1 in the effectiveness analysis project; in terms of economics, the impact is assumed to be on a level of 2 in the economic analysis project based on the increased cost of treatment compared to monotherapy.
The method for intelligent analysis of repeat medication as described above, the method further comprising: the judgment condition of the repeated medication drug pair/group is selected or adjusted according to the combined influence level/score of the repeated medication of the drug pair/combination for the patient. For example, A, B two drugs contain the same component c, the original judgment condition is that the two drugs are used together, and repeated drug administration may exist, but in the repeated drug administration influence analysis process, when the same component c in A, B two drugs does not exceed a certain usage amount, the comprehensive influence level/score of the drug on the repeated drug administration of a patient is low, the judgment condition can be adjusted to A, B for use together, and the repeated drug administration may exist when the component c exceeds a certain usage amount.
And 4, step 4: and generating a medication optimization scheme.
Based on the repeat medication analysis results of the patient's medication regimen, if there is a possibility of repeat medication between the medications, a medication optimization regimen is generated according to the relevant rules in the repeat medication database. Or setting the influence level of the repeated medication optimization starting according to the business requirement, and starting the generation of the medication optimization scheme and the comparison of the related medication scheme after the influence of the repeated medication reaches or exceeds the set level.
In the invention, the purpose of optimizing the medication scheme is to adjust the medication scheme of related medicines according to the related rules of repeated medication, so as to eliminate or reduce the adverse effect of repeated medication, and the specific method for optimizing the medication scheme comprises the following steps: adjusting at least one of a combination scheme of related drugs, adjusting related drugs, performing related medication monitoring or other treatment methods, and the like.
Adjusting the relevant drug combination regimen comprises: adjusting the medication time scheme of the related medicaments, adjusting the treatment course scheme of the related medicaments, adjusting the dosage scheme of the related medicaments, adjusting the using method scheme of the related medicaments and the like. The method specifically comprises the following steps: adjusting at least one of the administration frequency, the time interval between the administration of the drugs, the number of days of use, the amount of the administered drugs, the route of administration, the site of administration, and the method of use, and combinations of two or more thereof.
The adjustment of the administration time of the related drugs means that the administration interval between two or more drugs is prolonged by adjusting the administration frequency or administration time of the drugs, thereby reducing or eliminating the influence of repeated administration. The possible adjustment range of the use time of the related medicine is comprehensively analyzed through factors such as pharmacokinetics, disease characteristics, patient compliance and the like. The specific adjusting method comprises the following steps: according to the related rule of the relationship between the repeated medication influence of the drug pair/group in the drug repeated medication database and the medication time interval and the reasonable medication time range of each drug in the drug pair/group in which the repeated medication possibly exists, the medication time scheme of the drug pair/group, which can reduce the adverse influence of the repeated medication to the minimum under the condition of conforming to the respective reasonable medication time range of each related drug, is the optimal scheme of the medication time. The adjustment target of the adverse effect of repeated medication can also be set, the adverse effect of repeated medication can be reduced to the medication time scheme meeting the setting target by adjusting the medication time scheme, and the medication time optimization scheme can be a medication time optimization scheme or a collection of a plurality of time schemes. Such as: the application time of omeprazole and ranitidine can be adjusted if the patient has a night acid breakthrough phenomenon, and the omeprazole is taken in the morning and the ranitidine is taken before the sleep.
The adjustment of the treatment course of the related medicines means that the influence of repeated medicine application is reduced or eliminated by adjusting the using days of the medicines. The possible adjustment range of the treatment period of the related medicaments is analyzed through factors such as disease characteristics, the disease severity of the patient and the like. The specific adjusting method comprises the following steps: according to the relevant rules of the relation between the repeated medication influence of the medication pairs/groups in the medication repeated medication database and the medication use days and the reasonable use days range of each medication in the medication pairs/groups which may have repeated medication, the medication pair/group use days scheme which can reduce the adverse effect of repeated medication to the minimum under the condition of being in line with the respective reasonable use days range of each relevant medication is the medication course optimization scheme. The treatment course optimization scheme can be a medicine treatment course optimization scheme, and can be one or a collection of a plurality of time schemes. Such as: for a high-risk TIA or light ischemic stroke patient within 24h, the clopidogrel and aspirin combined medication scheme is adopted for treating the patient for 90 days, the bleeding risk of the patient can be increased due to the fact that the dual antiplatelet exceeds 21 days, the risk of the recurrent event of the stroke is obviously reduced by adjusting the using days of the aspirin to 21 days and then using the clopidogrel alone to 90 days, and meanwhile, the bleeding risk is reduced to the minimum.
Adjusting the dosage of the relevant drug as described above means reducing or eliminating the effect of repeat administration by increasing or decreasing the dosage of one or more of the drug pairs/groups in which repeat administration may be present. The possible adjustment range of the dosage of the related medicine is analyzed through factors such as a blood concentration model, the severity of the disease of the patient, the dosage of the medicine and the like. The specific adjusting method comprises the following steps: according to the rules related to the influence of repeated medication of the drug pairs/groups in the repeated medication database and the usage amount of the drugs and the reasonable dosage range of each drug in the drug pairs/groups with the possibility of repeated medication, the drug pair/group dosage scheme which can reduce the adverse influence of repeated medication to the minimum under the condition of meeting the respective reasonable dosage range of each related drug is the optimal scheme of the usage amount of the drugs. The adjustment target of the adverse effect of repeated medication can also be set, the adverse effect of repeated medication can be reduced to the dosage scheme meeting the setting target by adjusting the dosage scheme of the medicine, the dosage scheme can be a medicine usage optimization scheme, and the medicine usage optimization scheme can be one or a collection of a plurality of time schemes. Such as: for the essential hypertension patient who cannot sufficiently control blood pressure by single medicine treatment, the administration scheme of the valsartan amlodipine 160mg/10mg and the valsartan 240mg is adopted, and the blood pressure reducing curative effect of the valsartan exceeding 320mg is not increased along with the increase of the dosage, so that the treatment cost of the patient can be reduced by reducing the using amount of the valsartan.
The related medicine use method is adjusted by adjusting the administration route, the administration part and the use method, so that the adverse effect of repeated administration is reduced. The possible adjustment range of the related medicine using method is comprehensively analyzed through factors such as pharmacokinetics, disease characteristics, patient compliance and the like. Such as: the A medicine and the B medicine are used together, the A medicine and the B medicine may be repeatedly used in the intravenous injection, if the A medicine can be injected intravenously or intramuscularly, the influence of repeated use can be reduced or eliminated by adjusting the administration route of the A medicine.
The related medicine adjustment scheme comprises the following steps on the basis of the original medicine scheme: at least one of reducing the amount of the medicine, increasing the amount of the medicine, replacing the medicine and the like. The method specifically comprises the following steps: the method comprises the steps of excluding one or more medicines in a medicine pair/group which possibly has repeated medicine use from a medicine use scheme, replacing one or more medicines in the medicine pair/group which possibly has repeated medicine use with other medicines which have the same clinical effect but do not have repeated medicine use or have small repeated medicine use influence, and adding new medicines on the basis of the existing medicine use scheme to reduce the adverse effect of the original repeated medicine use and the like.
The reduction of the medicines refers to the elimination of the influence of repeated medicine application by stopping one or more medicines in the original medicine scheme. The choice of drug to be used is discontinued, and factors include, but are not limited to, whether the drug is a first choice/first line treatment regimen for an indication, whether the drug is administered chronically, etc. Such as: for the drug regimen of hypoglycemia after the combined use of the metformin and the glyburide for the type 2 diabetes patients, if the blood sugar control of the patients with the metformin alone before the addition of the glyburide reaches the standard, the influence of repeated use can be eliminated by stopping the glyburide. Because metformin is the first choice drug for the drug treatment of type 2 diabetes and alone generally does not cause hypoglycemia, the hypoglycemic side effects of glyburide are common and severe.
The replacement of the medicines refers to the reduction or elimination of the influence of repeated medicine application by replacing one or more medicines in the original medicine scheme. The medicine replacement includes the replacement of dosage forms, the replacement of specifications, the replacement of manufacturers, the replacement of medicine names and the like. Whether the drugs in the original medication scheme are replaceable or not, and factors include but are not limited to whether the drugs are the first-choice/first-line treatment scheme for a certain indication or not, whether the drugs have alternatives or not, whether the current business unit has the alternatives of the drugs or not, whether the drugs are taken for a long time or not and the like. Such as: for the drug regimen that patients with type 2 diabetes mellitus who are subjected to single-drug therapy and have substandard blood sugar control jointly use metformin and glyburide to cause hypoglycemia, because the hypoglycemia side reaction of the glyburide is common and serious, the glyburide can be replaced by glipizide or insulin secretagogues, alpha-glycosidase inhibitors and other oral hypoglycemic drugs with low hypoglycemia risk.
The increased medicine is to reduce the adverse effect of repeated administration by adding new medicine on the basis of the original administration scheme, prevent or treat adverse reaction possibly caused by the original administration scheme by adding the medicine, or generate new clinical effect by interacting with the medicine in the original administration scheme or weaken the toxicity of the medicine in the original administration scheme so as to reduce or eliminate the adverse effect of repeated administration in the original administration scheme. Such as: for a medication scheme that patients with type 2 diabetes mellitus suffer from hypoglycemia after combined use of metformin and glyburide, if the patients suffer from conscious disturbance, 20-40 ml of 50% glucose solution can be injected into an vein, or 0.5-1.0 mg of glucagon is injected into the muscle.
The related medication monitoring scheme comprises: monitoring at least one of the blood concentration of the relevant drug, monitoring relevant indexes, monitoring relevant symptoms, monitoring relevant physiological conditions and the like. Such as: for a regimen in which hypoglycemia occurs after metformin and glyburide are used in combination in type 2 diabetics, blood glucose should be monitored 1 time every 15 minutes on the basis of actively managing hypoglycemia until hypoglycemia is corrected.
In the present invention, the method for optimizing the medication scheme may be a combination of the above methods, that is, two or more methods of adjusting the medication time scheme of the relevant drugs, adjusting the treatment period scheme of the relevant drugs, adjusting the dosage scheme of the relevant drugs, adjusting the usage method scheme of the relevant drugs, reducing the drugs, adding the drugs, replacing the drugs, and monitoring the relevant medication may be performed simultaneously. When generating and screening relevant optimization schemes, the relevant rules can be applied in combination to find a more optimal medication scheme.
The repeated medication database repeated medication rule comprises repeated medication which is possible to happen to a drug pair/group combination under different use conditions, and the relationship between a drug use scheme and the repeated medication under the use conditions. Due to the different types of repeat dosing that occurs between different drug pairs/groups, different drug pairs/groups may have different repeat dosing effects and levels of effect on the patient when combined under different drug use conditions and different drug use regimens. Under certain medicine use conditions, the related medicine use scheme is adjusted, so that the repeated medicine use can be optimized, and the adverse effect of the repeated medicine use on the treatment of patients is avoided or reduced.
When the medication optimization scheme is generated, the range, the sequence and the optimization target of the medication optimization scheme generation of different medication usage schemes under different medication usage conditions can be set according to business needs, such as: the optimized dosage regimen range may be set to optimize one of the dosage time, dosage, usage method, drug reduction, drug replacement, etc. of a drug pair/group in which repeat drug administration may occur, or may be set to optimize a combination of two or more of them. For another example, the order of generation of the medication optimization plan for a particular drug use condition and drug use plan may be set as: the method comprises the steps of medicine taking time adjustment, medicine taking amount combined adjustment, medicine reduction, medicine replacement and monitoring, wherein an optimization target is set to be the mode that the influence level of repeated medicine taking is adjusted from the serious level to the medium level through optimization, and the range of an optimization scheme is set to be the optimization scheme which completely meets the optimization target or the optimization scheme with the best optimization effect or the first optimization scheme which meets the optimization target according to the set optimization sequence. According to the setting and the actual medication situation, the medication optimization schemes of different medication use schemes under different medication use conditions may be one scheme or a plurality of schemes, and the medication use schemes may not have the medication optimization schemes capable of meeting the setting conditions under the medication use conditions. If the analysis shows that no medication optimization scheme which can meet the setting conditions exists, the related users can be prompted to adjust the setting so as to analyze and generate a relatively optimized medication scheme, or the original medication use scheme is prompted to be the relatively optimal medication use scheme under the medication use conditions.
The medication optimization schemes of different medication use conditions and different medication use schemes can be generated by manual or related system analysis after related rules are obtained through a medication repeat medication database according to related settings. Or through manual or systematic analysis, directly storing the medication optimization schemes of different medication use conditions and different medication use schemes in a repeated medication database, establishing a medication optimization scheme library, and extracting the relevant schemes from the repeated medication database when the medication use conditions and the medication use schemes meet relevant conditions.
And 5: the original medication scheme is comprehensively compared with the medication optimization scheme, and the reasonability of repeated medication of the patient is evaluated.
According to the setting and the actual medication situation, the medication optimization scheme may be one or more schemes, the original medication scheme and the medication optimization scheme are comprehensively compared, and the comprehensive effect and influence of the original medication scheme and each medication optimization scheme on the patient are evaluated.
The analysis items for the integrated analysis of the medication use regimen may include effectiveness-related analyses: applicable population, medication purpose, indication/applicable condition, effective rate, onset time and the like, and can also comprise at least one of the importance degree of the medication purpose corresponding to the medicine, the importance degree of the medicine in a treatment scheme and the like; safety correlation analysis: at least one item of contraindication, cautionary events, adverse reactions, interaction, allergy and the like; and (4) economic correlation analysis: at least one item of price, treatment cost, medical insurance, administrative management requirements, and the like; suitability correlation analysis: availability, difficulty of use, taste/smell, frequency of use, time of use, etc.
The method further comprises the following steps: under different use conditions, carrying out rationality/compliance analysis on the medication optimization scheme and the original medication scheme, and setting levels/scores corresponding to different analysis results of related rationality analysis items under different use conditions in each analysis item; setting a medication scheme comprehensive analysis model combining medication schemes and various reasonability related analysis items under different use conditions according to business requirements; analyzing and comparing the medication optimization scheme with the original medication scheme through a comprehensive analysis model to obtain respective rationality/compliance comprehensive grade/score; and comparing the rationality/compliance comprehensive grade/score of the medication optimization scheme with the original medication scheme, and evaluating the rationality of each medication scheme. When the comprehensive effect of the optimization scheme and the original scheme on the patient is compared, a rationality comprehensive analysis model formed by analysis results of all analysis projects can be set according to the service requirements of different service units, so that quantitative evaluation results of comprehensive analysis can be obtained according to the relationship between all the analysis projects and the rationality comprehensive analysis results and the analysis results of the optimization scheme and the original scheme on all the analysis projects. The business unit may be an analysis unit that divides a business scenario in each dimension and combination of administration, medical institution, department, doctor, patient, medicine, disease, and the like. The repeated medication comprehensive influence analysis model can be set by a user or can be a model established after analysis of big data and artificial intelligence.
Such as: the level of influence of the analysis items such as security, effectiveness, economy, suitability, and the like can be set to 1 to 5, and the higher the level, the more adverse the influence.
Patient information: depression, no significant improvement after 6 weeks of paroxetine treatment.
The original medication scheme is as follows: paroxetine, 50mg daily, decreasing by 10mg weekly; amitriptyline was administered at 50mg daily, increasing to 150-300mg daily.
Through repeated drug administration analysis, the patient uses two antidepressant drugs simultaneously, repeated drug administration may exist, the patient information is compared with relevant rules in a repeated drug administration database, the influence of the possible repeated drug administration is analyzed, and a drug administration optimization scheme is generated:
the original medication scheme is as follows: in the aspect of effectiveness, due to the ineffectiveness of paroxetine, amitriptyline has not yet reached the preferential dose, and the level of the original medication in the effectiveness analysis project is assumed to be 2; in terms of safety, 5-HT syndrome may occur when two drugs are used together, assuming that the original drug regimen is on the order of 2 in the safety analysis item.
The first optimization scheme is as follows: paroxetine was discontinued and amitriptyline was administered at 50mg daily, increasing to 150-300mg daily.
In terms of efficacy, amitriptyline has not reached a priority dose, assuming the effect is on the order of 2 in the efficacy analysis project; in terms of safety, paroxetine suddenly stops taking medicine, and serious adverse reactions may occur, assuming this effect is on the order of 4 in the safety analysis project.
And the second optimization scheme is as follows: the paroxetine is 50mg daily, 10mg is decreased every week until stopping the drug, and after 2-4 days of drug stopping, the amitriptyline is 50mg daily and is increased to 150 mg-300 mg daily.
In the aspect of effectiveness, because amitriptyline starts new drug titration after paroxetine stops taking the drug for 2-4 days, the patient is exposed to a non-treatment state for a long time before the amitriptyline reaches an effective dose, the condition of the patient cannot be effectively controlled, and the condition of the patient can even be worsened, and the influence is assumed to be 4 in the level of an effectiveness analysis project.
To sum up: although repeated administration may exist in the original medication scheme of the patient, the original medication scheme is superior to the optimized medication scheme through comprehensive comparison.
When the medication scheme is comprehensively analyzed, exclusion rules can be set for the results of the related analysis items of each medication use scheme, that is, if the analysis result of a certain analysis item or the comprehensive analysis results of more than two items meet the exclusion rules, the medication use scheme needs to be excluded under the existing medication use conditions, and cannot be used for treating patients.
The original medication scheme is comprehensively compared with the medication optimization scheme, if the original medication scheme is superior to the medication optimization schemes under the medication use condition, the original medication scheme is shown to be a better reasonable medication scheme without adjustment, and if the medication optimization scheme superior to the original medication scheme exists, the original medication scheme is shown to be adjusted.
Or directly comparing the optimized scheme with the original scheme when the medication optimized scheme is generated, namely comprehensively comparing the difference of the optimized scheme and the original scheme on the analysis results of the analysis items related to the rationality of the medication scheme and on the basis of the relation model of the analysis items and the comprehensive analysis results by repeating the medication database, wherein if the comprehensive analysis results of the optimized scheme are superior to the original scheme, the original scheme needs to be adjusted. The drug-use optimization scheme may optimize the original drug-use scheme in terms of repeated drug use and may bring about other problems, so that the optimization scheme needs to be comprehensively compared with the original scheme.
The usage of the comparison result can be set when the original medication scheme is compared with the medication optimization scheme comprehensively, if the optimization scheme needs to be set to a certain degree compared with the comprehensive comparison result of the original scheme, the original medication scheme is prompted to be adjusted, and the comparison result can include the difference of comprehensive grade/score or the ratio of comprehensive score to a certain degree.
The method further comprises the following steps: according to business needs, a method for setting the influence of the medicine on/group repeated use under different use conditions and the comparison condition of the rationality/compliance comprehensive level/score of the original medicine use scheme and the medicine use optimization scheme to be applied to the analysis result of the repeated use under different business scenes is set, and then the analysis result of the repeated use is applied according to the influence possibly caused by the medicine on/group repeated use and the comparison condition of the rationality/compliance comprehensive level/score of the original medicine use scheme and the medicine use optimization scheme possibly existing in the medicine use of a patient under the set and related use conditions, wherein the specific application mode is as follows: at least one of reasonable, reminding, warning, prohibiting, prompting, recommending, guiding and the like. Through the analysis, if the fact that the patient medication scheme is possible to have repeated medication is obtained, the conclusion on the repeated medication analysis is reasonable when the optimal/set optimal scheme is considered to be met through comprehensive comparison; when the original medication scheme needs to be adjusted due to repeated medication through comprehensive comparison, the medication scheme can be given according to the service setting: reminding, warning, forbidding, prompting and other measures to prevent adverse effects on patients caused by repeated medication, and the specific prompt information can be as follows: prompting that repeated medication exists in the original medication scheme, prompting that a drug pair/group of the repeated medication exists, prompting the influence/influence level possibly caused by the repeated medication, prompting/recommending a medication optimization scheme, prompting the comparison condition of the original medication scheme and the optimization scheme, guiding a patient to correctly use the drug and the like. If the result of the analysis is that no medication regimen adjustment is required, the result of the analysis may not be displayed.
If the original medication scheme is comprehensively compared with the medication optimization scheme, if the original medication scheme is superior to the medication optimization schemes under the medication use condition, the original medication scheme is prompted to be a better reasonable medication scheme without adjustment, and if the medication optimization scheme superior to the original medication scheme exists, the original medication scheme is prompted to be an unreasonable scheme without adjustment.
The guidance of correct medication for a patient herein refers to guidance of correct understanding of medication use information related to medication optimization schemes for the patient, and includes: the medication time, the medication scheme, the dosage, the self-monitoring of adverse effects of repeated medication, the attention points related to repeated medication and the like, and the guidance mode can comprise the following steps: written material, video, voice, timed reminders, etc.
The method for intelligent analysis of repeat medication as described above, the method further comprising: the repeated medication database can also store the optimal medication scheme or the optimized medication scheme related to repeated medication under different use conditions, and is applied to at least one of auditing, recommending, analyzing, evaluating and managing the medication scheme of the patient. The specific use scenarios include: when the using conditions of the medicines of the patients meet the relevant conditions, and the medication scheme meets the optimal medication scheme or the optimized medication scheme, the conclusion on the repeated medication analysis is reasonable; when the use condition of the medicine of the patient meets the relevant condition, extracting the relevant optimal medicine scheme or optimized medicine scheme from the database, and assisting a doctor prescription or a pharmacist to give a medicine scheme suggestion; when the medicine use information of the patient meets related conditions, extracting a related optimal medicine use scheme or an optimal medicine use scheme from the database to assist a doctor/pharmacist in adjusting the medicine use scheme; when the medicine use information of the patient meets related conditions, the related optimal medicine scheme or optimized medicine scheme is extracted from the database, and a pharmacist is assisted in auditing/commenting the medicine scheme. When the optimized medication schemes are multiple under the current medication use condition, the optimized medication schemes can be set, and the optimized medication schemes with the rationality comprehensive evaluation scores exceeding the set scores or the optimized medication schemes with the rationality comprehensive evaluation scores exceeding the set scores are extracted or extracted.
The method for intelligent analysis of repeated drug administration as described above further comprises analyzing the outcome of treatment including but not limited to cure, stabilize, improve, not improve, worsen, fail, die, etc., of the patient on a regular or irregular basis. And comparing the basic information and the drug use information of the patient with the related information and rules in the repeated drug use database for the patient with unexpected treatment outcome, and analyzing whether repeated drug use exists, the type of the repeated drug use, the actual influence of the repeated drug use and the influence level of the repeated drug use.
The method for intelligent analysis of repeat medication as described above, further comprising recommending a repeat medication adverse outcome treatment regimen for medications that did not meet a therapeutic goal due to repeat medication between medications. The repeated medication database can also comprise repeated medication adverse effect processing rules, and the medication use information and the medication results are compared with the related information and rules in the repeated medication database to recommend a repeated medication adverse effect processing scheme. The treatment scheme comprises at least one of adverse reaction treatment schemes such as emetic, gastric lavage, adsorption, catharsis, excretion promotion, oxygen absorption, fluid replacement and the like, adjustment of a related drug administration time scheme, adjustment of a related drug dosage scheme, adjustment of a related drug use method scheme, drug replacement, drug inactivation, development of related drug administration monitoring or other treatment methods and the like.
In the analysis process of the repeated drug use of the drug, if new information is obtained, the intelligent analysis of the repeated drug use can be carried out again by combining the new information.
In the invention, the method for intelligently analyzing repeated medication further comprises the step of establishing a multi-dimensional element attribute dictionary for drug use, wherein the multi-dimensional element attribute dictionary is used for processing matching/comparison of data from different sources, different data structures, different descriptions and different data standards, such as personal information, drug use information and the like of patients, and related information and rules of a drug repeated medication database, and comprises a fuzzy matching algorithm. The medicament use multi-dimensional element attribute dictionary comprises at least one of a standard dictionary, a synonym corresponding dictionary, a multi-dimensional element attribute corresponding dictionary and a fuzzy matching dictionary of medicament use related element attributes, and comprises data such as synonyms, structures, combinations and mutual corresponding relations of the dimension element attributes related to the items. The medication use multi-dimensional element attribute dictionary may be built separately or included in a repeat-of-medication database.
In the invention, besides adopting the medicine to use the multidimensional element attribute dictionary for matching, the matching/comparison of the personal basic information, the medicine use information of the patient and the related information and rules of the repeated medicine database can be processed by methods such as a voice recognition technology, a word segmentation technology, a semantic recognition technology, translation of different languages, an OCR recognition technology, a virtual reality technology, an augmented reality technology, a gesture recognition technology and the like.
A second embodiment of the present invention is seen in figure 2. Fig. 2 is a block diagram of a patient repeat-use management system of the present invention. The method comprises the following steps:
the database unit is used for storing a repeated medication database;
an information extraction unit for extracting drug use information;
a repeated medication analysis unit for comparing the medication use information with the related information and rules of the repeated medication database, analyzing the repeated medication situation of the patient, generating a medication optimization scheme if repeated medication possibly exists among the medications, and generating a repeated medication management scheme according to the situation of comprehensive comparison and analysis of the original medication scheme and the medication optimization scheme,
and the output unit is used for outputting the analysis result related to repeated medication and the management scheme.
The technical features of the repeated medication intelligent analysis system and the repeated medication intelligent analysis method of the present invention are in one-to-one correspondence, and the description of the method can be referred to, and will not be repeated herein.
The repeated medicine-taking intelligent analysis system can be an independently used system or a system which is mutually called with other systems through a data interface; the system can be used by a single machine, and can also be installed on a local area network server for local users of the local area network to use; the system can also be installed in a private cloud server to support private cloud users to use, and can also be installed in the Internet to provide services for Internet users.
A third embodiment of the present invention is seen in fig. 3. Fig. 3 is a hardware block diagram of an intelligent analysis apparatus for repeat-dose of the present invention. The invention discloses a device for intelligently analyzing repeated medication, which comprises:
the database module is used for storing a repeated medicine database;
the information extraction module is used for extracting the medicine use information;
the repeated medication analysis module is used for comparing the medication use information with the related information and rules of the repeated medication database, analyzing the repeated medication condition of the patient, generating a medication optimization scheme if repeated medication possibly exists among the medications, generating a repeated medication management scheme according to the comprehensive comparison and analysis condition of the original medication scheme and the medication optimization scheme,
and the output module is used for outputting the related analysis result of the repeated medication and the management scheme.
The technical characteristics of the repeated-medication intelligent analysis device and the repeated-medication intelligent analysis method of the invention are in one-to-one correspondence, and the description of the method can be referred to, and is not repeated herein.
According to the intelligent analysis equipment for repeated medication, the repeated medication analysis module can be independently deployed, can be mutually called with other equipment through a data interface, and can also be directly installed on other equipment/instruments/robots; the system can be used by a single machine, and can also be installed on a local area network server for local users of the local area network to use; the system can also be installed in a private cloud server to support private cloud users to use, and can also be installed in the Internet to provide services for Internet users; the system can be deployed in a computing center to support the use of multiple user terminals, or deployed in multiple computing centers to support the use of multiple user terminals; the user terminal may be a desktop or a mobile device.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are merely exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.

Claims (12)

1. A method for intelligent analysis of repeat medication, the method comprising:
a repeated medicine-taking database is established,
the information of the use of the medicine is extracted,
the medicine use information is compared with the related information and the rules of the repeated medicine database, the repeated medicine use condition is analyzed,
if there may be repeat dosing between drugs, a dosing optimization plan is generated.
The repeat-use database includes information and rules common to drugs having the same composition or the same class of drugs under different conditions of use.
2. The method for intelligent analysis of repeat medication as recited in claim 1, wherein: the method also comprises the step of carrying out comprehensive analysis and comparison according to the original medication scheme and the medication optimization scheme, and evaluating the reasonability of the repeated medication of the patient.
3. The method for intelligent analysis of repeat medication according to any of claims 1 or 2, wherein: the method further comprises the step of adjusting the extraction range of the medicine use information according to the current medicine use condition of the patient.
4. A method of intelligent repeat-of-medication analysis as recited in any of claims 1-3, wherein: the method also comprises the step of taking one of the measures of ignoring, reminding and supplementing, supplementing according to the setting, supplementing forcibly and the like according to the specific situation of lacking information if the information needed by certain analysis items is lacked due to incomplete related medicine use information in the process of repeated medicine use analysis.
5. The method for intelligent analysis of repeat medication according to any of claims 1-4, wherein: the method also comprises the steps of analyzing the possible influence of repeated drug administration on a patient when the drugs are administered according to different drug administration schemes under different drug administration conditions, and setting the corresponding grade/score of the relevant influence in each repeated drug administration influence analysis item; establishing a repeated medication influence comprehensive analysis model for synthesizing analysis results of repeated medication influence analysis items according to business requirements; the comprehensive grade/score of the influence of the drug pair/group combination on the repeated drug administration of the patient can be analyzed through the corresponding grade/score in each repeated drug administration influence analysis project and the comprehensive analysis model of the repeated drug administration influence under different use conditions according to different drug use schemes.
6. The method for intelligent analysis of repeat medication according to any of claims 1-3, wherein: the medication optimization scheme comprises the following steps: adjusting at least one of a combination scheme of related drugs, adjusting related drugs, performing related medication monitoring or other treatment methods, and the like.
7. The method for intelligent analysis of repeat medication according to any of claims 1-3, wherein: the method also comprises the steps of carrying out comprehensive rationality analysis and comparison on the medication optimization scheme and the original medication scheme under different using conditions, and setting the corresponding grade/score of different analysis results of related rationality analysis items of the medication scheme in each analysis item; setting a medication scheme comprehensive analysis model combining each rationality analysis project of the medication scheme according to business requirements; analyzing the medication optimization scheme and the original medication scheme through a comprehensive analysis model to obtain respective reasonability comprehensive grade/score; and comparing the rationality comprehensive analysis results of the medication optimization scheme and the original medication scheme, and evaluating the rationality of the original medication scheme.
8. The method for intelligent analysis of repeat medication according to any of claims 1-7, wherein: the method further comprises that according to the business needs and settings of different users, the results of the repeated medication analysis of the patient medication scheme can be: at least one of reasonable, reminding, warning, prohibiting, prompting, recommending, guiding and the like.
9. The method for intelligent analysis of repeat medication according to any of claims 1-7, wherein: the method also comprises that the repeated medication database can also comprise the optimal medication scheme or the optimized medication scheme related to repeated medication under different using conditions, and the method is applied to at least one item of auditing, recommending, analyzing, evaluating and managing the medication scheme of the patient.
10. The method for intelligent analysis of repeat medication according to any of claims 1-9, wherein: the method also includes recommending a repeat-of-medication remediation regimen for the treatment goal not being met due to repeat-of-medication between the medications. The repeated medication database can also comprise repeated medication remedy rules, and the medication use information and the medication treatment results are compared with the related information and rules in the repeated medication database to recommend a corresponding repeated medication remedy scheme.
11. A system for intelligent analysis of repeat medication is characterized in that the system comprises a database unit for storing a repeat medication database,
an information extraction unit for extracting drug use information,
a repeated medication analysis unit for comparing the medication use information with the related information and rules of the repeated medication database, analyzing the repeated medication situation of the patient, generating a medication optimization scheme if there is a possibility of repeated medication between the medications, and generating a repeated medication management scheme according to the situation of comprehensive comparison and analysis between the original medication scheme and the medication optimization scheme,
and the output unit is used for outputting the analysis result related to repeated medication and the management scheme.
12. An apparatus for intelligent analysis of repeat medication intake, the apparatus comprising: the database module is used for storing a repeated medicine database;
the information extraction module is used for extracting the medicine use information;
a repeated medication analysis module for comparing the medication use information with the related information and rules of the repeated medication database, analyzing the repeated medication condition of the patient, if repeated medication possibly exists among the medications, generating a medication optimization scheme according to the related settings, and generating a repeated medication management scheme according to the comprehensive comparison and analysis condition of the original medication scheme and the medication optimization scheme,
and the output module is used for outputting the related analysis result of the repeated medication and the management scheme.
CN202011114977.8A 2020-10-18 2020-10-18 Intelligent analysis method, system and equipment for repeated medication Pending CN112233765A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011114977.8A CN112233765A (en) 2020-10-18 2020-10-18 Intelligent analysis method, system and equipment for repeated medication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011114977.8A CN112233765A (en) 2020-10-18 2020-10-18 Intelligent analysis method, system and equipment for repeated medication

Publications (1)

Publication Number Publication Date
CN112233765A true CN112233765A (en) 2021-01-15

Family

ID=74118786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011114977.8A Pending CN112233765A (en) 2020-10-18 2020-10-18 Intelligent analysis method, system and equipment for repeated medication

Country Status (1)

Country Link
CN (1) CN112233765A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113012782A (en) * 2021-03-05 2021-06-22 中国医学科学院阜外医院 Method and device for recommending medicine
US20220285029A1 (en) * 2021-03-04 2022-09-08 Acer Incorporated Medication risk evaluation method and medication risk evaluation device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103902791A (en) * 2011-12-20 2014-07-02 西安福安创意咨询有限责任公司 Clinic safe and reasonable drug use decision supporting method
CN104616233A (en) * 2015-02-13 2015-05-13 杜雨阳 Method and system of obtaining interaction prompt information between medicines
CN108630322A (en) * 2018-04-27 2018-10-09 厦门大学 Drug interaction modeling and methods of risk assessment, terminal device and storage medium
CN111489820A (en) * 2020-03-13 2020-08-04 上海洛书医药科技有限公司 Artificial intelligence-based auxiliary diagnosis and treatment system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103902791A (en) * 2011-12-20 2014-07-02 西安福安创意咨询有限责任公司 Clinic safe and reasonable drug use decision supporting method
CN104616233A (en) * 2015-02-13 2015-05-13 杜雨阳 Method and system of obtaining interaction prompt information between medicines
CN108630322A (en) * 2018-04-27 2018-10-09 厦门大学 Drug interaction modeling and methods of risk assessment, terminal device and storage medium
CN111489820A (en) * 2020-03-13 2020-08-04 上海洛书医药科技有限公司 Artificial intelligence-based auxiliary diagnosis and treatment system

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220285029A1 (en) * 2021-03-04 2022-09-08 Acer Incorporated Medication risk evaluation method and medication risk evaluation device
EP4064286A1 (en) * 2021-03-04 2022-09-28 Acer Incorporated Medication risk evaluation method and medication risk evaluation device
CN113012782A (en) * 2021-03-05 2021-06-22 中国医学科学院阜外医院 Method and device for recommending medicine

Similar Documents

Publication Publication Date Title
CN110853723A (en) Intelligent medicine guidance method, system and equipment
CN111223546A (en) Method, system and equipment for intelligently auditing treatment scheme
CN110717082A (en) Method, system and equipment for reasonable use and compliance analysis of medical instrument
CN110797115A (en) Intelligent recommended medical examination and inspection method, system and equipment
CN113871026A (en) Medical risk assessment system and method
CN111145916A (en) Method, system and equipment for intelligently recommending surgical plan
CN111223543A (en) Method, system and equipment for intelligently guiding treatment scheme
CN113314226A (en) System, method and equipment for intelligently analyzing anaphylactic reaction
Samuels et al. Use of non-vitamin, non-mineral (NVNM) supplements by hospitalized internal medicine patients and doctor–patient communication
CN113130026A (en) System, method and computer medium for checking internet prescription
CN113921124A (en) Medical expense management method and system
Cannon The economic impact of peanut allergies
CN111933247A (en) Method, system and equipment for intelligent management of drug interaction
CN111028915A (en) Method, system and equipment for intelligently auditing surgical scheme
CN113506622A (en) Intelligent diagnosis and analysis system and use method thereof
CN111028936A (en) Method, system and equipment for medical examination and reasonable compliance analysis of inspection
Moukafih et al. Impact of clinical pharmacy services in a hematology/oncology ward in Morocco
CN112233745A (en) Method, system and equipment for intelligently recommending antimicrobial drugs
CN113808699A (en) Intelligent comparison system for treatment schemes and application method thereof
Yang et al. National opioid prescribing trends in emergency departments by provider type: 2005–2015
CN112233765A (en) Intelligent analysis method, system and equipment for repeated medication
CN111128401A (en) Method, system and equipment for intelligently recommending surgical items
Rees et al. Supporting self-care of long-term conditions in people with dementia: A systematic review
CN110942819A (en) Method, system and equipment for intelligently auditing surgical projects
Bernard et al. Patient factors that affect opioid use among adults with and without chronic pain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination